COMPARATIVE EVALUATION OF THE ADVERSE EFFECTS OF INJECTABLE THERAPIES FOR BODY WEIGHT CONTROL
DOI:
https://doi.org/10.56238/levv17n60-033Keywords:
Obesity, Semaglutide, Tirzepatide, Adverse EffectAbstract
Obesity is a multifactorial chronic disease considered one of the main global public health problems, being associated with several metabolic comorbidities. In recent years, injectable incretin-based therapies, such as semaglutide and tirzepatide, have been widely used in the treatment of excess weight, promoting appetite reduction, improved glycemic control, and significant weight loss. However, these medications have adverse effects, mainly gastrointestinal, such as nausea, vomiting, diarrhea, and constipation. Furthermore, the indiscriminate use of these substances, often without professional supervision, can increase the risk of complications such as dehydration, hypoglycemia, and pancreatitis. This study aims to analyze and compare the main adverse effects associated with the use of semaglutide and tirzepatide, based on recent scientific evidence. This is a qualitative and comparative literature review, based on articles published between 2019 and 2025. The results indicate that both therapies are effective for weight loss, but tirzepatide presents a higher intensity of side effects. Therefore, the need for individualized clinical monitoring to ensure treatment safety is reinforced.
Downloads
References
APOVIAN, Caroline M. et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, v. 100, n. 2, p. 342-362, 2015. Acesso em: 07 abr. 2026. DOI: https://doi.org/10.1210/jc.2014-3415
BRAY, G. A. et al. Pharmacological treatment of obesity. The Lancet, v. 391, n. 10138, p. 2509–2524, 2018. Acesso em: 07 abr. 2026.
DAVIES, Melanie J. et al. Semaglutide 2.4 mg once weekly in adults with overweight or obesity. The Lancet, v. 397, n. 10278, p. 971–984, 2021. Disponível em: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/fulltext. Acesso em: 07 abr. 2026. DOI: https://doi.org/10.1016/S0140-6736(21)00213-0
FRÍAS, Juan P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, v. 385, n. 6, p. 503–515, 2021. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa2107519. Acesso em: 07 abr. 2026. DOI: https://doi.org/10.1056/NEJMoa2107519
GASTALDELLI, Amalia et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI). The Lancet Diabetes & Endocrinology, v. 10, n. 6, p. 393–406, 2022. Acesso em: 07 abr. 2026. DOI: https://doi.org/10.1016/S2213-8587(22)00070-5
GIL, Antonio Carlos. Métodos e técnicas de pesquisa social. 7. ed. São Paulo: Atlas, 2019.
JASTREBOFF, Ania M. et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, v. 387, n. 3, p. 205–216, 2022. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038. Acesso em: 07 abr. 2026. DOI: https://doi.org/10.1056/NEJMoa2206038
LUDVIK, B. et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, v. 398, n. 10300, p. 583–598, 2021. Disponível em: DOI: https://doi.org/10.1016/S0140-6736(21)01443-4. DOI: https://doi.org/10.1016/S0140-6736(21)01443-4
MARSO, Steven P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, v. 375, n. 19, p. 1834–1844, 2016. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa1607141. Acesso em: 07 abr. 2026. DOI: https://doi.org/10.1056/NEJMoa1607141
MÜLLER, Timo D. et al. Glucagon-like peptide-1 (GLP-1). Molecular Metabolism, v. 30, p. 72–130, 2019. DOI: https://doi.org/10.1016/j.molmet.2019.09.010
PEREIRA, A. S. et al. Metodologia da pesquisa científica. Santa Maria: UFSM, 2018.
RODRIGUEZ, Patricia J. et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Internal Medicine, v. 184, n. 9, p. 1056–1064, 2024. Disponível em: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2821080. Acesso em: 07 abr. 2026. DOI: https://doi.org/10.1001/jamainternmed.2024.2525
VERMA, Subodh et al. Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3). EClinicalMedicine, v. 55, 2023. DOI: https://doi.org/10.1016/j.eclinm.2022.101737
WADDEN, Thomas A. et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA, v. 325, n. 14, p. 1403–1413, 2021. DOI: https://doi.org/10.1001/jama.2021.1831
WEGHUBER, Daniel et al. Once-weekly semaglutide in adolescents with obesity. New England Journal of Medicine, v. 387, n. 24, p. 2245–2257, 2022. Acesso em: 07 abr. 2026. DOI: https://doi.org/10.1056/NEJMoa2208601
WILDING, John P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, v. 384, n. 11, p. 989–1002, 2021. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183. Acesso em: 07 abr. 2026. DOI: https://doi.org/10.1056/NEJMoa2032183
WORLD HEALTH ORGANIZATION. Obesity and overweight. 2023. Disponível em: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Acesso em: 07 abr. 2026.
